Atlantic Health System’s Overlook Medical Center participates in unique, nationwide ‘MIND Trial’ for patients suffering from deep bleeds within the brain

Bleeding that occurs within the deep recesses of the brain – known as an intracranial hemorrhage, or ICH -- represents 10-15% of all strokes but can be among the most devastating.

“Deep intracranial bleeds can be highly destructive,” shared Paul Saphier, M.D., neurovascular surgeon with Overlook Medical Center, during the Atlantic Health System Neuroscience 19th Annual ‘Stroke Symposium’ in May 2019.

Sign Up for Chatham Newsletter
Our newsletter delivers the local news that you can trust.

Unfortunately, “open surgery isn’t a viable option for these small, deep areas, and the administration of tPA -- an FDA-approved clot-busting drug which can reverse the effects of a stroke for the 20-30% of stroke victims who are medically eligible to receive it -- has been shown to help some, but not many.”  As a result, Saphier said, “’best medical management’ of their underlying conditions (such as high blood pressure, high cholesterol, etc.) has been the standard of care for these patients, but up to half of them don’t survive beyond 30 days and only 20% of those who do can live independently at six months.”

By contrast, Saphier has seen relatively greater success using a surgical procedure that involves the Artemis Neuro Evacuation Device, an FDA-approved, minimally-invasive endoscopic tool.  “Performed through a small incision, the device enables image-guided surgery and provides continuous irrigation as we remove the hemorrhage, all while improving visual acuity and minimizing damage to surrounding tissue,” he said.

According to Saphier, Overlook Medical Center is among the first sites to participate in a study of the ‘Minimally-Invasive Neuro Evacuation Device,’ or “MIND” Trial, which launched in January 2018 and aims to enroll 500 patients. 

Relative to the often ineffective ‘best medical management’ approach for many ICH patients, “MIND surgery allows us to access deep places of the brain with a truly minimally-invasive technique that we feel could be a standard of care within the next 5-10 years,” Saphier said.